Reagan Jarvis, Ph.D., CEO

April 21 | 9:15am | Gaudi 2 Ballroom

Sodertalje, Sweden


In-Person Presentation

Anocca is leveraging its highly scalable precision analysis technologies to develop transformative TCR-T immunotherapies to treat cancer and other serious diseases. The company has pioneered a proprietary industrialised analytical cell biology platform that enables a deep understanding of disease specific T cell biology to deliver highly targeted cell-based therapies. Anocca has a fully integrated R&D infrastructure, with a range of scalable analytics platforms leveraging extensive libraries of engineered cells and complemented by a clinical manufacturing and process development facility. The company’s platform has generated a broad pipeline of high value assets focusing on distinct disease franchises. The company expects to progress several TCR-T therapies to the clinic. Anocca was founded in 2014 and has raised over $100M USD in funding from leading Nordic investors Swedbank Robur Ny Teknik, Ramsbury Invest, Mellby Gård, Nidoco, and Michano AB.

By using this website you agree to accept our Privacy Policy and Terms & Conditions